The pleiotropic effects of ethacrynic acid

American Journal of Therapeutics

Volumn 16, Issue 1, 2009, Pages 102-104

  Somberg, John C ^a,b   Molnar, Janos ^b  

^a RUSH UNIVERSITY   (United States)

^b American Institute of Therapeutics   (United States)

Author keywords

Cancer therapy; Drug resistance; Ethacrynic acid; Glutathione S transferase; Pleiotropy

Indexed keywords

ARTESUNATE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; DOXORUBICIN; ETACRYNIC ACID; GLUTATHIONE TRANSFERASE; LOOP DIURETIC AGENT; MELPHALAN;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; GLAUCOMA; HUMAN; LYMPHATIC LEUKEMIA; NONHUMAN; OPEN ANGLE GLAUCOMA; PLEIOTROPY; PRIORITY JOURNAL; RADIATION RESPONSE; SHORT SURVEY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DIURETICS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ETHACRYNIC ACID; GLAUCOMA; GLUTATHIONE TRANSFERASE; HUMANS; RADIATION-SENSITIZING AGENTS;

EID: 60249099489     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181961264     Document Type: Short Survey

References (28)

1. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994;54:4313-4320.
2. Ciaccio PJ, Tew KD, LaCreta FP. Enzymatic conjugation of chlorambucil with glutathione by human glutathione S-transferases and inhibition by ethacrynic acid. Biochem Pharmacol. 1991;42:1504-1507.
3. Gate L, Tew KD. Glutathione S-transferases as emerging therapeutic targets. Expert Opin Ther Targets 2001;5:477-489.
4. O'Dwyer PJ, LaCreta F, Nash S, et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res. 1991;51:6059-6065.
5. Vukovic L, Osmak M. Reversal of carboplatin resistance in human laryngeal carcinoma cells. Neoplasma. 1999;46:335-341.
6. Rhodes T, Twentyman PR. A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines. Br J Cancer. 1992;65:684-690.
7. Lewis AD, Duran GE, Lau DH, et al. Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. Int J Radiat Oncol Biol Phys. 1992;22:821-824.
8. Efferth T, Volm M. Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. In Vivo. 2005;19:225-232.
9. Caffrey PB, Zhu M, Zhang Y, et al. Rapid development of glutathione-S-transferase-dependent drug resistance in vitro and its prevention by ethacrynic acid. Cancer Lett. 1999;136:47-52.
10. Awasthi S, Singhai SS, He N, et al. Modulation of doxorubicin cytotoxicity by ethacrynic acid. Int J Cancer. 1996;68:333-339.
11. Petrini M, Conte A, Caracciolo F, et al. Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient. Br J Haematol. 1993;84:409-410.
12. Depeille P, Cuq P, Passagne I, et al. Combined effects of GSTPI and MRPI in melanoma drug resistance. Br J Cancer. 2005;93:216-223.
13. Vicente JR, Ortega VV, Jordana MC. The effects of different antineoplastic agents and of pretreatment by modulators on three melanoma lines. Cancer. 1998;82:495-502.
14. Lacreta FP, Brennan JM, Nash SL, et al. Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. J Pharmacol Exp Ther. 1994;270:1186-1191.
15. Sheehan D, Meade G. Chemical modulation of chemotherapy resistance in culture oesophageal carcinoma cells. Biochem Soc Trans. 2000;28:27-32.
16. Ciaccio PJ, Shen H, Kruh GD, et al. Effects of chronic ethacrynic acid exposure on glutathione conjugation and MRP expression in human colon tumor cells. Biochem Biophys Res Commun. 1996;222:111-115.
17. Shen H, Ranganathan S, Kuzmich, et al. Influence of ethacrynic acid on glutathione s-transferase transcript and protein half-lives in human colon cancer cells. Biochem Pharmacol. 1995;50:1233-1238.
18. Zhao G, Liu C, Wang R, et al. The synthesis of α,ß- unsaturated carbonyl derivatives with the ability to inhibit both glutathione S-transferase P1-1 activity and the proliferation of leukemia cells. Bioorg Med Chem. 2007;15:2701-2707.
19. Zhao G, Yu T, Want R, et al. Synthesis and structure-activity relationship of ethacrynic acid analogues on glutathione-s-transferase P1-1 activity inhibition. Bioorg Med Chem. 2005;13:4056-4062.
20. Wang R, Li C, Song D, et al. Ethacrynic acid butyl-ester induces apoptosis in leukemia cells through a hydrogen peroxide-mediated pathway independent of glutathione S-transferase P1-1 inhibition. Cancer Res. 2007;67:7856-7864.
21. Ding D, Jiang H, Wang P, et al. Cell death after coadministration of cisplatin and ethacrynic acid. Hearing Res. 2007;226:129-139.
22. Khil MS, Kim HS, Pinto JT, et al. Ethacrynic acid: a novel radiation enhancer in human carcinoma cells. Int J Radiat Oncol Biol Phys. 1996;34:375-380.
23. Oronsky AL, Triner L, Steinsland OS, et al. Effect of sulphydryl binding compounds on the inflammatory process. Nature. 1969;223:619-621.
24. Han Y, Englert JA, Delude RL, et al. Ethacrynic acid inhibits multiple steps in the NF-kB signaling pathway. Shock. 2005;23:45-53.
25. Killeen ME, Englert JA, Stolz DB, et al. The phase 2 enzyme inducers ethacrynic acid, DL-sulforaphane, and oltipraz inhibit lipopolysaccharide- induced high-mobility group box 1 secretion by RAW 264.7 cells. J Pharmacol Exp Ther. 2006;316:1070-1079.
26. Kokkola R, Sundberg E, Ulfgren AK, et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 2002;46:2598-2603.
27. Lin CW, Wang Y, Challa P, et al. Transscleral diffusion of ethacrynic acid and sodium fluorescein. Mol Vis. 2007;13:243-252.
28. Shimazaki A, Kirihara T, Rao PV, et al. Effects of the new ethacrynic acid oxime derivative SA12590 on intraocular pressure in cats and monkeys. Biol Pharm Bull. 2007;30:1445-1449.